Public Policy Letters, Statements, Legal Briefs, & Other Responses
-
Group Sign-on Letter to CMS Supporting CY 2019 PFS Changes to Reduce E/M Documentation Burden
-
ACMG Letter to Congress Concerning the FDA Technical Assistance for the Diagnostic Accuracy and Innovation Act (DAIA)
-
ACMG Comments to CMS Concerning CLFS Gapfill Preliminary Determinations for GS Codes 81425, 81426, and 81427
-
Group Sign-on Letter to Congress Concerning the Diagnostic Accuracy and Innovation Act (DAIA)
-
ACMG Comments to CMS on Proposed NCD for Coverage of NGS for Medicare Beneficiaries with Advanced Cancer (CAG-00450N)
-
Group Sign-on Letter to Congress Supporting the Local Coverage Determination Clarification Act of 2017
-
ACMG/AMP/IDSA Joint Congressional Briefing on LDTs
-
ACMG-AMP Joint Webinar on Regulatory Oversite of LDTs (slides)
-
ACMG-AMP Joint Webinar on Regulatory Oversite of LDTs (recording)
-
ACMG One-Pager on FDA’s Proposed Regulatory Framework for LDTs